TICKERNERD
Menu
RAPPRAPPHealthcare · Biotechnology

RAPP Stock Forecast: Rapport Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 30 Sept 2026
$34
+1.76% on the day

The 13 Wall Street analysts covering Rapport Therapeutics, Inc. hold a median 12-month price target of $59 — +75.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 29 Sept 2026 — in the lower half.

Market cap
$1.6B
Ticker Nerd rank
43 / 100
Median analyst target
$59
Analysts covering
13
Revenue$0.0
Operating income−$60.8M
Net income−$56.6M
Free cash flow−$41.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.6%
1M
−31.1%
YTD
+10.7%
1Y
+13.1%
From 52W high
−36.0%
From 52W low
+37.9%
$24
$53
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RAPP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Rapport Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 29 Sept 2026
43 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
91
Value
68
Quality
55
Accruals
54
Issuance
43
Size
38
Revisions
33
Volatility
32
Growth
30

Momentum (91): The shares have been drifting up relative to others.

Growth (30): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RAPP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RAPP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60$70$80Oct 25Jan 26Apr 26Jul 26RAPPHigh $80Median $59Low $50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
13 Buy0 Hold0 Sell
Low $50Median $59High $80

The green dot is the last close — the median target sits +75.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
16 Sept 2026BTIGMaintainsBuy$65 → $75
19 Aug 2026BTIGReiteratesBuy$65
19 Aug 2026BTIGReiteratesBuy—
12 Aug 2026HC Wainwright & Co.MaintainsBuy$40 → $66
12 Aug 2026HC Wainwright & Co.MaintainsBuy—
5 Aug 2026BTIGReiteratesBuy$65
5 Aug 2026BTIGReiteratesBuy—
16 July 2026BTIGReiteratesBuy$65
16 July 2026BTIGReiteratesBuy—
24 June 2026Leerink PartnersInitiatesOutperform$52
24 June 2026Leerink PartnersInitiatesOutperform—
21 May 2026BTIGMaintainsBuy—
19 May 2026Truist SecuritiesAssumesBuy$44 → $56
8 May 2026BTIGReiteratesBuy—
22 Apr 2026BTIGReiteratesBuy—
11 Mar 2026BTIGMaintainsBuy—
11 Mar 2026Wells FargoMaintainsOverweight—
2 Feb 2026Wells FargoInitiatesOverweight—
9 Dec 2025HC Wainwright & Co.MaintainsBuy—
8 Dec 2025BTIGReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RAPP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RAPP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Sept 2026, Rapport Therapeutics, Inc. returned +13.1% against +15.7% for the S&P 500, dividends included.

RAPP vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Oct 25Jan 26Apr 26Jul 26RAPPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RAPP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
5
Fundamentals

Rapport Therapeutics, Inc. (RAPP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
21.2×

Cheaper than 35% of US stocks

Price / sales
80.2×

Cheaper than 4% of US stocks

Price / book
3.8×

Cheaper than 26% of US stocks

EV / EBITDA
−7.7×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−767.6%

Higher than 6% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−40.0%

Higher than 24% of US stocks

Return on assets
−25.8%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Rapport Therapeutics, Inc. (RAPP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Rapport Therapeutics, Inc. has a market value of $1.6B and an enterprise value of $1.2B.

  • Revenue in the twelve months to 30 June 2026: $20.0M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$137.2M, a −685.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.04.

  • Free cash flow in the twelve months to 30 June 2026: −$97.1M.

  • Rapport Therapeutics, Inc. spent $5K on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 48.0M.

  • Trailing P/E: 21.2×; forward P/E: −6.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Rapport Therapeutics, Inc. employs 84 people — $238K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 29 Sept 2026

Data provided by Twelve Data

Peers

RAPP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RAPPRapport Therapeutics, Inc.$1.6B
43
SNDXSyndax Pharmaceuticals, Inc.$1.6B
59
INVAInnoviva, Inc.$1.6B
87
TSHATaysha Gene Therapies, Inc.$1.6B
41
STOKStoke Therapeutics, Inc.$1.6B
54
ADRXADARx Pharmaceuticals, Inc.$1.6B
0
KRSAKorsana Biosciences, Inc.$1.5B
39

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Rapport Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RAPP news & analysis

Rapport: Bipolar Mania Readout May Distort True Value Of Anti-Seizure Med - Rating Upgrade

Seeking Alpha · 24 Sept 2026neutral

Rapport Therapeutics stock fell about 18% as investors weighed updates on lead candidate RAP-219 and anticipated Phase 2 bipolar mania data. RAP-219 showed strong efficacy in focal onset seizures, with up to 90% median reduction in clinical seizures, while analysts view the bipolar mania readout as potentially more instructive for safety than efficacy.

Why it matters — RAPP watchers would care because the upcoming Phase 2 bipolar mania readout may shape perceptions of RAP-219's safety profile and influence the true value of the anti-seizure candidate beyond its focal onset seizure opportunity.

Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania Transcript

Seeking Alpha · 23 Sept 2026neutral

Rapport Therapeutics (RAPP) held a discussion on its RAP-219 Phase II trial and the unmet needs in bipolar mania, according to a Seeking Alpha transcript of the event.

Why it matters — A RAPP watcher would care because RAP-219 is a key pipeline candidate, and the discussion provides insight into the company's development plans and the treatment gap it aims to address in bipolar mania.

4 Biotech Stocks With Key Clinical Readouts Expected This Fall

Zacks Investment Research · 22 Sept 2026neutral

Zacks Investment Research reports that four biotech stocks, including Rapport Therapeutics (RAPP), face key clinical readouts this fall that could influence their drug and vaccine pipelines. The item lists RAPP among KOD, CLDX, and PCVX as companies with these upcoming readouts.

Why it matters — A RAPP watcher would care because these upcoming clinical readouts could influence the company's drug pipeline and prospects.

Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday

Benzinga · 16 Sept 2026positive

Benzinga reports that top Wall Street analysts changed their outlooks on several companies, with the headline highlighting a forecast of a roughly 76% potential rally for Rapport Therapeutics (RAPP). The piece lists analyst rating changes, including upgrades and downgrades, for various names.

Why it matters — A RAPP watcher would care because an analyst forecast suggesting a large potential upside for the stock reflects a notable shift in analyst sentiment that could influence investor attention.

Rapport Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewsWire · 2 Sept 2026neutral

Rapport Therapeutics announced that its management plans to participate in upcoming investor conferences, including a fireside chat at the Cantor Global Healthcare Conference in New York City on Wednesday, September 9, 2026. The company is a clinical-stage biotechnology firm focused on developing small molecule precision medicines for neurological and psychiatric disorders.

Why it matters — A RAPP watcher would be interested because the company's participation in investor conferences provides opportunities for management to communicate with investors about its clinical-stage programs.

FAQ

Frequently asked questions about RAPP stock

What is the RAPP stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Rapport Therapeutics, Inc. have a median 12-month price target of $59, with estimates ranging from $50 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RAPP stock a buy right now?

Of the 13 analysts covering Rapport Therapeutics, Inc., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rapport Therapeutics, Inc. 43 out of 100 across roughly 4,600 US stocks as at 29 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RAPP?

As at 29 Sept 2026, Rapport Therapeutics, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (91 of 100).

Will RAPP stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +75.6% from the last close, and Ticker Nerd's factor model ranks Rapport Therapeutics, Inc. 43 out of 100 as at 29 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RAPP stock forecast for 2030?

No analyst covering Rapport Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RAPP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $80 over the next 12 months.

How has RAPP stock performed over the past year?

Rapport Therapeutics, Inc. returned +13.1% over the 12 months to 30 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Rapport Therapeutics, Inc. do?

Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for central nervous system disorders.

What is the latest news on RAPP?

The most recent item we track (Seeking Alpha, 24 Sept 2026): "Rapport: Bipolar Mania Readout May Distort True Value Of Anti-Seizure Med - Rating Upgrade". Rapport Therapeutics stock fell about 18% as investors weighed updates on lead candidate RAP-219 and anticipated Phase 2 bipolar mania data. RAP-219 showed strong efficacy in focal onset seizures, with up to 90% median reduction in clinical seizures, while analysts view the bipolar mania readout as potentially more instructive for safety than efficacy.

Company

About Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for central nervous system disorders. The company’s work centers on precision neuroscience, using its RAP technology platform to target receptor-associated proteins that help regulate neuronal signaling. Its pipeline includes investigational programs for focal epilepsy, peripheral neuropathic pain, bipolar disorder, chronic pain, migraine, and hearing or vestibular disorders. Rapport Therapeutics also develops receptor-targeted candidates in areas such as AMPA receptor modulation and nicotinic acetylcholine receptor biology, reflecting a broad research effort across neurological and psychiatric conditions. Headquartered in Boston, Massachusetts, Rapport Therapeutics plays a specialized role in the biotechnology market by advancing targeted therapies designed for complex brain and nervous system diseases.

CEO Mr. Abraham N. Ceesay M.B.A. · 84 employees · United States · https://www.rapportrx.com